Jett Foundation has announced the launch of a capital campaign to fund the construction of Jett’s Place, a premier wellness and retreat center designed as a dedicated sanctuary for individuals and families affected by Duchenne muscular dystrophy (DMD). The announcement marks the organization’s most ambitious milestone to date, with the campaign anchored by two transformative $1 million donations from the Emilson Family and ITF Therapeutics.
Located on a 10-acre campus in Norwell, Massachusetts, Jett’s Place will serve as Jett Foundation’s national headquarters and offer barrier-free accessibility, specialized wellness care, adaptive nature and recreation, and educational programs developed with input from Duchenne families. The facility aims to provide a supportive environment where the Duchenne community can access resources, connect with others, and improve quality of life.
The capital campaign has set a goal of $10.7 million, and during its quiet phase, it has already raised over $5 million. Jett Foundation is now inviting broader community support to bring the project to fruition. According to the foundation, Jett’s Place will be a first-of-its-kind center, addressing the unique needs of those living with Duchenne, a progressive neuromuscular disorder that affects approximately 1 in 5,000 live male births and some females.
Duchenne muscular dystrophy is diagnosed during childhood and leads to a loss of motor, pulmonary, and cardiac function, with no cure currently available. Children with Duchenne typically lose the ability to walk around age 12 and face premature death in their early to mid-twenties. Jett Foundation has worked since 2001 to empower individuals and families impacted by Duchenne through transformative programming, educational opportunities, and ongoing support.
ITF Therapeutics, the U.S. affiliate of Italfarmaco Group, focuses on developing and commercializing treatments for rare diseases. The company’s $1 million donation underscores its commitment to the Duchenne community, as it combines commercial execution with direct engagement from advocates, researchers, clinicians, and families. More information about ITF Therapeutics can be found at www.itftherapeutics.com.
Jett Foundation’s capital campaign for Jett’s Place represents a significant step forward in providing dedicated support for the Duchenne community. The center is expected to become a vital resource, offering a range of services tailored to the needs of individuals and families navigating the challenges of DMD. For more details about the project and how to contribute, visit www.jettfoundation.org.
